Stoke Therapeutics Inc.
8.65
-0.27 (-3.03%)
At close: Jan 14, 2025, 3:59 PM
8.68
0.35%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 7
Market Cap 458.16M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.08
PE Ratio (ttm) -4.16
Forward PE n/a
Analyst Buy
Ask 9.74
Volume 670,354
Avg. Volume (20D) 624,552
Open 9.00
Previous Close 8.92
Day's Range 8.42 - 9.13
52-Week Range 4.09 - 17.58
Beta undefined

About STOK

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome,...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2019
Employees 110
Stock Exchange NASDAQ
Ticker Symbol STOK

Analyst Forecast

According to 8 analyst ratings, the average rating for STOK stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 131.21% from the latest price.

Buy 87.50%
Hold 12.50%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Stoke Therapeutics Inc. is scheduled to release its earnings on Mar 24, 2025, during market hours.
Analysts project revenue of $2.97M, reflecting a 6.03% YoY growth and earnings per share of -0.56, making a -6.67% decrease YoY.
1 month ago · Source
+12.07%
Stoke Therapeutics shares are trading higher after... Unlock content with Pro Subscription
2 months ago · Source
+1.53%
Stoke Therapeutics shares are trading higher on possible continued strength following Q3 reported financial results yesterday. Also, Needham and HC Wainwright & Co. reiterated Buy ratings on the stock.